Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation

@article{Mauskopf2000CostEffectivenessMO,
  title={Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation},
  author={Dr Josephine A. Mauskopf and Anke Richter and Lieven Annemans and Grant Maclaine},
  journal={PharmacoEconomics},
  year={2000},
  volume={18},
  pages={239-251}
}
Background: Cytomegalovirus (CMV) disease may occur following renal transplantation and has been shown to have health and cost consequences in this setting. Objective: To compare the cost effectiveness of different CMV management strategies for renal transplant patients: prophylaxis with (i) oral valaciclovir or (ii) intravenous ganciclovir; viral testing for CMV followed by (iii) pre-emptive therapy with intravenous ganciclovir or (iv) adjustment of immunosuppression and intensive monitoring… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Similar Papers

Loading similar papers…